I agree that this site is using cookies. You can find further informations here.
X
Dodick, DW
76  results:
Search for persons X
?
1

P.015 Monthly migraine days, acute medication use-days, and..:

Dodick, DW ; Lipton, RB ; Nahas, SJ...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.  49 (2022)  s1 - p. S11-S11 , 2022
Link: https://doi.org/10.1017/..
 
?
2

P.029 Oral Daily Atogepant for the Preventive Treatment of ..:

Lipton, RB ; Pozo-Rosich, P ; Blumenfeld, AM...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.  48 (2021)  s3 - p. S28-S28 , 2021
Link: https://doi.org/10.1017/..
 
?
3

P.034 Eptinezumab Demonstrated Early Relief from Episodic a..:

Dodick, DW
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.  48 (2021)  s3 - p. S30-S30 , 2021
Link: https://doi.org/10.1017/..
 
?
4

P.010 Efficacy, safety, and tolerability of ubrogepant for ..:

Lipton, RB ; Dodick, DW ; Ailani, J...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.  46 (2019)  s1 - p. S16 , 2019
Link: https://doi.org/10.1017/..
 
?
5

A.07 Efficacy, safety, and tolerability of ubrogepant for t..:

Dodick, DW ; Lipton, RB ; Ailani, J...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.  46 (2019)  s1 - p. S9-S10 , 2019
Link: https://doi.org/10.1017/..
 
?
6

P.024 Educational needs in migraine care: results from a mi..:

Peloquin, S ; Leroux, E ; Shapero, G...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.  45 (2018)  s2 - p. S22-S22 , 2018
Link: https://doi.org/10.1017/..
 
?
7

Development of a Responder Definition for the Migraine Phys..:

Kawata, AK ; Hsieh, R ; Sapra, S...
Value in Health.  19 (2016)  7 - p. A383 , 2016
Link: https://doi.org/10.1016/..
 
?
8

EHMTI-0099. Migraineur perception regarding family burden f..:

Buse, DC ; Dodick, DW ; Adams, AM
The Journal of Headache and Pain.  15 (2014)  S1 - p. , 2014
Link: https://doi.org/10.1186/..
 
?
9

OnabotulinumtoxinA for treatment of chronic migraine: PREEM..:

Diener, HC ; Dodick, DW ; DeGryse, RE.
The Journal of Headache and Pain.  14 (2013)  S1 - p. , 2013
Link: https://doi.org/10.1186/..
 
?
10

The percent of chronic migraine patients who responded to o..:

Silberstein, S ; Dodick, DW ; DeGryse, RE..
The Journal of Headache and Pain.  14 (2013)  S1 - p. , 2013
Link: https://doi.org/10.1186/..
 
?
11

Migraine headache is present in the aura phase – a prospect..:

Hansen, JM ; Lipton, RB ; Dodick, DW...
The Journal of Headache and Pain.  14 (2013)  S1 - p. , 2013
Link: https://doi.org/10.1186/..
 
?
12

Migraine headache is present in the aura phase – a prospect..:

Hansen, JM ; Lipton, RB ; Dodick, DW...
The Journal of Headache and Pain.  1 (2013)  Suppl 1 - p. P130 , 2013
Link: https://doi.org/10.1186/..
 
?
13

OnabotulinumtoxinA for treatment of chronic migraine: PREEM..:

Diener, HC ; Dodick, DW ; DeGryse, RE.
The Journal of Headache and Pain.  14 (2013)  Suppl 1 - p. P204 , 2013
Link: https://doi.org/10.1186/..
 
?
14

Headache symptoms of the PREEMPT population:

Dodick, DW ; DeGryse, RE ; Turkel, CC
The Journal of Headache and Pain.  1 (2013)  Suppl 1 - p. P99 , 2013
Link: https://doi.org/10.1186/..
 
?
15

OnabotulinumtoxinA for chronic migraine: efficacy, safety, ..:

Aurora, SK ; Dodick, DW ; DeGryse, RE.
The Journal of Headache and Pain.  1 (2013)  Suppl 1 - p. P199 , 2013
Link: https://doi.org/10.1186/..
 
1-15